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Background: Intestinal hyper-permeability plays a critical role in the etiopathogenesis of inflammatory bowel
disease (IBD) by affecting the penetration of pathogens, toxic compounds and macromolecules.
1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the active form of vitamin D, has been shown to be an important regulator
of IBD and recent epidemiology suggests that patients with IBD have an impaired vitamin D status. The purpose of
this study is to investigate the possible protective effects of 1,25(OH)2D3 on mucosal injury and epithelial barrier
disruption on dextran sulfate sodium (DSS)-induced acute colitis model.
Methods: We used DSS-induced acute colitis model to investigate the protective effects of 1,25(OH)2D3 on
mucosal injury and epithelial barrier integrity. Severity of colitis was evaluated by disease activity index (DAI), body
weight (BW) change, colon length, histology, myeloperoxidase (MPO) activity, and proinflammatory cytokine
production including tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). In vitro the protective role of
1,25(OH)2D3 was assessed by incubating Caco-2 cells with or without DSS and measuring transepithelial
electrical resistance (TEER) and fluorescein isothiocyanate dextran (FITC-D). The intestinal permeability was
analyzed by FITC-D, bacterial translocation and measurement of lipopolysaccharide (LPS). Ultrastructural
features of the colon tissue and Caco-2 cell monolayer were observed by electron microscopy. Expressions of
tight junction (TJ) proteins in the colon mucosa and Caco-2 cells were detected by immunohistochemistry,
immunofluorescence, Western blot and real-time fluorescent quantitative PCR, respectively.
Results: DSS-induced acute colitis model was characterized by a reduced BW, AUC of BW, serum calcium,
higher DAI, AUC of DAI, shortened colon length, elevated MPO activity, worsened histologic inflammation,
increased mononuclear cell numbers in mesenteric lymph nodes (MLNs) and colonic lamina propria (LP), and
enhanced proteins and mRNA levels of TNF-α and IFN-γ. 1,25(OH)2D3 markedly increased expressions of TJ
proteins and mRNA and decreased the FITC-D permeability and the level of LPS. Furthermore, 1,25(OH)2D3
abrogated bacterial translocation to MLNs and ameliorated ultrastructural features of the colon epithelium by
scanning electron microscopy (SEM). In vitro, 1,25(OH)2D3 increased TEER, TJ proteins and mRNA expressions,
decreased the FITC-D permeability, and preserved structural integrity of the TJ in Caco-2 cells.* Correspondence: xiaolanzh@126.com
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http://www.biomedcentral.com/1471-230X/12/57Conclusions: 1,25(OH)2D3 may play a protective role in mucosal barrier homeostasis by maintaining the integrity of
junction complexes and in healing capacity of the colon epithelium. 1,25(OH)2D3 may represent an attractive and
novel therapeutic agent for the adjuvant therapy of IBD.
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1,25-dihydroxyvitamin D3Background
Inflammatory bowel disease (IBD), comprised of Crohn’s
disease (CD) and ulcerative colitis (UC), are chronic dis-
eases characterized by aberrant immune responses to lu-
minal bacteria in genetically susceptible subjects [1].
Although the exact pathogenesis of IBD is unknown, the
initiation of inflammation and relapse of disease activity
are associated with engagement of the innate and adpa-
tive immune responses, including increased production
in tumor necrosis factor-α (TNF-α) and interferon-γ
(IFN-γ) in the intestine [2,3]. These pro-inflammatory
cytokines are potential pathogenic factors, which impair
mucosal barrier function and intestinal permeability. A
disproportionate large number of first-degree relatives of
patients with IBD have increased intestinal permeability,
which suggests barrier dysfunction may be an early de-
fect. Previous studies have demonstrated a decreased ex-
pression of junction complex proteins in the intestinal
mucosa of patients with IBD [4,5]. Impaired gut epithe-
lial barrier function may lead to persistent immune reac-
tions, thus augmenting the gut inflammation [6].
The intestinal epithelial barrier consists of epithelial
cells and intercellular junctions [7-9]. Tight junction
(TJ) is the apical-most intercellular structure in epithelial
cells, accounting for the cell-cell adhesion, polarity, and
permeability barrier to paracellular transport of the
solutes [10]. The TJ creates a semipermeable barrier,
separating different organ compartments. It is composed
of a large number of protein components, such as occlu-
dins, claudins and zonula occludens-1 (zo-1). Both
claudins and occludins are coupled either directly or in-
directly to cytoskeleton actin filaments with zo-1 and
other factors. Distributions of claudins vary along the
gut epithelial cells and express different types in the con-
necting cells through the formation of zipper structures
[11,12]. Once the mucosal barrier is breached, the sub-
mucosa is exposed to a vast pool of luminal antigens, in-
cluding food and bacteria, and the innate immune
responses are engaged to produce large amounts of cyto-
kines. Therefore, maintaining TJ and barrier function
may provide potential benefits in the adjuvant therapy of
many gastrointestinal diseases, including IBD [13-15].
1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the active
form of vitamin D, has been shown to be an important
regulator in many experimental autoimmune diseases
[16-19]. A recent study has shown that vitamin D dir-
ectly modulates the T-cell antigen receptor (TCR) [20].In naive T cells, low expression of phospholipase
C (PLC)-γ1 is correlated with low TCR responsiveness.
The induction of PLC-γ1 was shown to be dependent on
vitamin D and vitamin D receptor (VDR) [21]. Studies
have implicated that the deficiency of VDR may lead to
exaggerated inflammatory responses [22,23]. Consistent
with its anti-inflammatory role, 1,25(OH)2D3 down-
regulates the expressions of many pro-inflammatory
cytokines, such as TNF-α, IFN-γ, and other cytokines
[24,25]. 1,25(OH)2D3 is also important to maintain
homeostasis in the respiratory tract, skin, and blood–
brain and blood-retinal barrier development. 1,25(OH)2D3
has been found to protect the intestinal mucosa from
various insults, combination therapy with angiotensin II
type 1 (AT II -1). Vitamin D analog markedly restored
glomerular filtration barrier structure, and the combined
treatment reversed the decline of slit diaphragm proteins,
such as nephrin and zo-1. Hence, 1,25(OH)2D3 may pre-
vent and treat these conditions [26-28].
The role of 1,25(OH)2D3 in the regulation of intestinal
barrier integrity and innate immune response in DSS-
induced acute colitis is unclear. Herein we hypothesized
that 1,25(OH)2D3 may play an important role in main-
taining the integrity of the intestinal mucosal barrier and
regulate the innate immunity, which implicates vitamin




The mice and the protocol involved in the study had
been approved by Institutional Animal Care and Use
Committee (IACUC). Approval ID: I07-038-3. All the
mice were housed under standard conditions per proto-
cols of IACUC and Hebei medical university vivarium in
a barrier facility (GB 14925-2001).
Animal studies
C57BL/6 mice were purchased from Vital River Labora-
tory Animal Technology Co. Ltd for in vivo studies
[License No. SCXK (Beijing) 2006-0009]. Acute colitis
was induced by administration of dextran sodium sulfate
(DSS; 40 000-50 000 MW; Sigma) drinking water. Male
mice of 8 weeks received either regular drinking water
(control) or 2% (w/v) DSS drinking water (model) ad
libitum for 7 days, after which the mice were resumed
on water for the remainder of the experiment. A total of
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1,25(OH)2D3−treated group (each group = 10). The mice
in the 1,25(OH)2D3−treated group received 1,25(OH)2D3
(Sigma) daily (0.2 ug/25 g/d) by intragastric administra-
tion for 14 days [29], and the mice in control and model
group were given normal saline without DSS.
Serum measurements
Mice were executed at the end of the experiment. Serum
was obtained, and Lipopolysaccharide (LPS) kit was
purchased from Sigma, and Calcium (587-A) kit was
purchased from Sigma. Serum calcium was measured
according to the manufacturer’s instructions. Vitamin D
deficiency was monitored by serum calcium analysis and
normal serum calcium levels for mice are 2.00–
2.75 mmol/L [29]. LPS was measured by Limulus quan-
titative azo color (LQAC) test.
Assessment of disease activity
Rachmilewitz DAI was assessed by an investigator
blinded to the protocol according to a standard scoring
system. The combined score composes of the extent of
body weight (BW) loss, stool consistency and detection
of occult blood (OB) in the stool, and they are defined
as follows. Loss in BW is scored as: no weight loss is
scored as 0, weight loss of 1–5% from baseline as 1,
5–10% as 2, 10–20% as 3, and more than 20% as 4. For
stool consistency, a score of 0 is assigned for wellformed
pellets, 2 points for pasty and semiformed stools that do
not adhere to the anus, and 4 points for liquid stools
that were adhere to the anus. For OB, a score of 0 point
is assigned for no blood, 2 points for positive hemoccult,
and 4 points for gross bleeding. These scores are added
together and divided by three, resulting in DAI ranging
from 0 (healthy) to 4 (maximal activity of colitis) [30]
and measured by area under curve (AUC).
Assessment of colonic injury and inflammation
Postmortem, the colon from the cecum to the anus was
removed, and the entire colon length was measured as a
marker of inflammation. On macroscopic examination,
the degree of colon damage was scored as follows: 0,
normal colon tissue; 1, minimal colon wall thickening
without congestion; 2, moderate colon wall thickening
with congestion; 3, moderate colon wall thickening,
rigidity, and congestion; and 4, marked colon wall thick-
ening, rigidity, and congestion. A segment of the prox-
imal colon was fixed in 10% formalin, and embedded in
paraffin; 4 um-thick sections of this tissue were stained
with hematoxylin and eosin (H&E). Histologic evaluation
was performed by two investigators blinded to the ani-
mal groups and the inflammation was graded as follows:
severity of inflammation (0–3: none, slight, moderate,
severe), extent of injury (0–3: none, mucosal, mucosaland submucosal, transmural), and crypt damage (0–4:
none, basal 1/3 damaged, basal 2/3 damaged, only sur-
face epithelium intact, entire crypt and epithelium lost).
Then each score was multiplied by a equivalent with the
percentage of tissue involved (×1: 0–25%, ×2: 26–50%,
×3: 51–75%, ×4: 76–100%).
Determination of myeloperoxidase (MPO) activity
MPO activity in homogenates of the colon was deter-
mined in this way: equal weights (100 mg wet weight) of
the colon from each group were suspended in 1 mL buf-
fer (0.5% hexadecyltrimethylammonium bromide in
50 mM phosphate buffer, pH 6.0) and sonicated at 30
cycles, twice for 30 s on ice. Homogenates were centri-
fuged, 2000 g, 4°C, and the supernatants were stored
at 80°C. The samples were incubated with a substrate
of odianisidine hydrochloride and the reaction was
carried out in a 96-well plate by adding to 290 μL
50 mM phosphate buffer, 3 μL substrate solution (con-
taining 20 mg/mL odianisidine hydrochloride), and 3 μL
H2O2 (20 mM). The samples (10 μL each well) were
added to each well to start the reaction. The reaction
was stopped by adding 3 μL sodium azide (30%), and
the plates were read for the assay at light absorbance
of 460 nm. MPO activity was determined by the curve
obtained from the standard MPO [31].
Isolation of mesenteric lymph nodes cells (MLNs) and
lamina propria mononuclear cells (LPMCs)
Mesenteric lymph nodes (MLNs) were placed in a petri
dish with 2 mL ice-cold RPMI 1640. Two prewet sterile
glass slides were used to smash MLNs, and then passed
through a 70 μm nylon cell strainer into a 50 mL Falcon
tube. Petri dish and glass slides were rinsed with an add-
itional 3 mL RPMI 1640, centrifuged, removed the
supernatant, and resuspended the pellet in 1.0 mL RPMI
1640 with 10% FCS. The cells were then counted. Isola-
tion of lamina propria mononuclear cells (LPMCs) was
described as follows: The dissected gut was opened lon-
gitudinally, transferred onto HBSS/5 mM EDTA and
incubated for 20 min at 37°C under slow rotation (40 g)
in a thermal incubator. Gut tissues were then transferred
onto a new petri dish with 1–2 mL collagenase solution
(100 mL of RPMI 1640 with 10% FCS [32]: Hyaluroni-
dase, 0.25 g; Collagenase type II, 0.15 g; DNase I,
0.025 g) and minced into about 1 mm-square pieces.
The minced tissues were then passed through a 70 um
cell strainer, then centrifuged, resuspended the pellet in
6 ml of 45% Percoll solution, overlaid the cell suspension
on top of 3 mL of the 72% Percoll solution, centrifuged,
carefully collected the cells, centrifuged again, aspirated
and resuspended the cells immediately in 500 μL RPMI
1640 with 10% FCS, and at last counted cells one by
one [33].
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For immunohistochemistry staining, antigens were re-
trieved by 10 min boiling in 10 mM citrate (pH 6.0). The
slides were stained with mouse monoclonal anti-claudin-1
antibody, anti-occludin antibody (Santa Cruez), and rabbit
polyclonal anti-zo-1 antibody (Invitrogen), rabbit poly-
clonal anti-IFN-γ antibody (Santa Cruez) and mouse
monoclonal anti-TNF-α antibody (sigma). After incuba-
tion with peroxidase-conjugated secondary antibody,
signals were visualized with a diaminobenzidine (DAB)
peroxidase substrate kit (Vector Laboratories). For TJ im-
munofluorescence staining, Caco-2 cell monolayer (fixed
in 95% ethanol) or colon sections were incubated with
mouse monoclonal anti-claudin-1 antibody, anti-occludin
antibody (Santa Cruez) and rabbit polyclonal anti-zo-1
antibodies (Invitrogen), then with an FITC-conjugated
secondary antibody or Cy3-conjugated secondary anti-
body. Slides were examined with a Leica DMIRE2 scan-
ning laser confocal microscope.
In vivo permeability
In vivo permeability assay was performed to assess bar-
rier function and performed by fluorescein isothiocyan-
ate dextran (FITC-D). Briefly, food and water were
withdrawn for 4 h, and mice were gavaged with perme-
ability tracer (60 mg/100 g BW of FITC-D (MW 4 000;
Sigma). Serum was collected retroorbitally 4 h after
FITC-D gavaged, and fluorescence intensity was mea-
sured (excitation, 492 nm; emission, 525 nm; Cytofluor 2
300 nm; Millipore), and FITC-D concentrations were
determined from standard curves generated by serial
dilution of FITC-D [34]. Permeability was calculated by
linear regression of sample fluorescence (Excel 5.0,
Microsoft Office). Detection of viable bacteria in MLNs
represented bacterial translocation from the lumen to
the MLNs. The MLNs of left colonic regions were
removed aseptically and dissected free of fat. A 0.1 ml
aliquot of each homogenate was plated into blood agar,
incubated at 37°C for 48 h, and then counted the num-
ber of colonies. The ratio of bacterial translocation was
presented for percentage.
Electron microscopy
Specimens were fixed, washed in acetone, critical point
dried, coated with gold by a sputter coater, and observed
under scanning electron microscope (SEM) fitted with a
lanthanum hexaboride cathode using an accelerating
voltage of 10 kV. Cell monolayer samples were fixed in
2% glutaraldehyde and postfixed in 1% osmium tetroxide
in 0.1 M phosphate buffer, pH 7.4, 1 h, 37°C. The tissues
were dehydrated in an ascending series of ethanol, infil-
trated with eponate 12 resin and then embedded and
polymerized, 70°C, 24 h. Resin-embedded blocks were
sectioned at 70 nm and collected on 200 mesh, formvar-coated copper grids. Grids teue were stained with uranyl
acetate and lead citrate and examined with a JEOL 1200
EX II transmission electron microscope (TEM).
Caco-2 cell culture
The Human Colon Carcinoma cell Line (Caco-2) was
purchased from Shanghai Institutes of Biochemistry and
Cell Biology for in vitro studies, and cultured in medium
supplemented with 10% fetal bovine serum (FBS) and
penicillin (50 U/ml)/streptomycin (50 μg/mL) in a 5%
CO2 atmosphere at 37°C. Caco-2 cell monolayer was
incubated with or without 2% DSS in the absence or
presence of 10−9, 10−8, 10−7 M of 1,25(OH)2D3 (adminis-
tered 2 h prior to DSS) for 48 h.
In vitro permeability
Paracellular permeability was determined by measuring
the apical to the basolateral flux of FITC-D using a modifi-
cation of previously described method [34]. Briefly, conflu-
ent epithelial monolayer on a 0.33 cm2, 0.4 μm pore size
permeable support was washed twice with Hanks’ balanced
salt solution containing calcium chloride and magnesium
sulfate (HBSS) and maintained at 37°C on a shaking
warm plate. FITC-D, 1 mg/mL, was added apically at
time 0, and 50 μL samples were removed from the baso-
lateral compartment at 30 min intervals from 0–360 min,
inclusively. Fluorescence intensity of each sample was
measured (excitation, 492 nm; emission, 525 nm; Cyto-
fluor 2 300 nm; Millipore Corp, Waters Chromatography,
Bedford, MA), and FITC-D concentrations were deter-
mined from standard curves generated by serial dilution
of FITC-D. Paracellular flux was calculated by linear re-
gression of sample fluorescence (Excel 5.0, Microsoft
WA, Power Macintosh 7200).
TEER measurement
For transepithelial electric resistance (TEER) measure-
ment, Caco-2 cells were cultured on collagen-coated
transwell polycarbonate membrane filter inserts (Corn-
ing). The cells were seeded at a density of 1 × 105 cell/
mL, the medium was changed every 1 or 2 days. The in-
tegrity of the monolayer was observed to accomplish
after culturing for 21 days, and evaluated by measuring
TEER with Millicell-Electrical Resistance System (ERS)
equipment (Millipore). Monolayer showing TEER values
of 130–200 ohm/cm2 were used for the experiments.
The monolayer cells were gently rinsed three times with
HBSS and equilibrated in the same solution for 30 min
at 37°C (inside volume; 400 μL, outside volume; 600 μL).
An aliquot (40 μL) of the apical solution was replaced by
the same volume of sample solution, containing each
compound at concentrations of 100–800 μg/mL, and the
TEER value of the monolayer was monitored for up to
360 min after adding to the sample solution [35].
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The expressions of the gene zo-1, occludin, claudin-1,
TNF-α and IFN-γ were characterized by real time Q-PCR.
Briefly, Total RNA was extracted from colons or Caco-2
cells using Trizol (Gibco) reversely transcripted into
cDNA according to manufacture’s protocol. The primers
for the zo-1, occludin and claudin-1 genes were as follows:
zo-1-Forward 5′-TCATCCCAAATAAGAACAGAGC-3′,
zo-1-Reverse 5′-GAAGAACAACCCTTTCATAAGC-3′,
(198 bp amplicon); occludin-Forward 5′-CTTTGGCTA
CGGAGGTGGCTAT-3′occludin-Reverse 5′-CTTTGGC
TGCTCTTGGGTCTG-3′, (86 bp amplicon); Claudin-1-
Forward 5′-GCTGGGT-TTCATCCTGGCTTCT-3′, Claudin-
1-Reverse 5′-CCTGAGCGGTCACGATGTTGTC-3′, (110 bp
amplicon); GAPDH-Forward 5′-GAGACCTTCAACACC
CCAGC-3′, GAPDH-Reverse 5′-ATGTCACGCACGATT
TCCC-3′, (263 bp amplicon); IFN-γ-Forward 5′-ATGAA
CGCTACACACTGCATCTT-3′IFN-γ-Reverse 5′-TTTC
TTCCACATCTATGCCACTT3′ (139 bp amplicon); TNF-
α-Forward5′-GGTTCTGTCCCTTTCACTCACT-3′TNF-
α-Reverse5′-GAGAAGAGGCTGAGACATAGGC-3′ (169 bp
amplicon). Reaction system: 10 μL 2.5×Real master
Mix, 1.25 μL 20×SYBR solution, 0.5 μL upstream pri-
mer, 0.5 μL downstream primer and 2 μL DNA tem-
plate was brought up to 25 μL with purified water. The
amplification was performed with Quantitect™ SYBRW
Green PCR Mastermix (Qiagen), using the following
time and temperature profile: 95°C for 5 min, 45 cycles
of 1 min at 95°C, 10 s at 60°C. Fluorescent quantitative
analysis was performed with the thermal cycler’s soft-
ware package to calculate the 5Ct value. The levels of
zo-1, occludin, claudin-1, TNF-α and IFN-γ were calcu-
lated by the 2-55Ct analysis. The 2-55Ct was presented
as the relative expression of the gene expression.
Western blot analysis
The concentration of proteins of colon tissue and caco-2
cells were determined using coomassie brilliant blue
assay, the extracts containing equal quantities of pro-
teins (100 μg) were electrophoresed in 8% polyacryl-
amide gel. Subsequently, the separated proteins were
transferred onto a nitrocellulose membrane. The mem-
brane was blocked for non-specific binding for 30 min
(5% skimmed milk in PBS), and then incubated over-
night at 4°C with rabbit anti-zo-1 polyclonal antibody
(1:100), mouse anti-claudin-1 monoclonal antibody
(1:200), anti-occludin antibody (1:200), rabbit polyclonal
anti-IFN-γ antibody (1:200), mouse monoclonal anti-
TNF-α antibody (1:200) and rabbit anti-GAPDH mono-
clonal antibody (1:100). The membrane was subse-
quently incubated at room temperature for 2 h with goat
anti-rabbit IgG (1:2 000)/anti-mouse IgG (1:2 000). Blots
were developed with enhanced chemiluminescence de-
tection reagents (Santa Cruz Biotechnology Inc),exposed on Kodak Xdmat blue XB-1 film and quantified
by Bandscan 5.0 software using GAPDH as internal con-
trol. Densitometry is reported using the integral optical
density value (IOD). The results were represented in the
form of IOD ratio of the target protein to GAPDH.
Statistical analysis
Data were expressed as mean ± standard deviation
(mean ± SD) and analyzed with SPSS 13.0 software. The
comparison of mean variability among all the groups
was conducted by one-way ANOVA analysis and two
group comparison with LSD test. A Student’s t-test was
carried out for independent samples. Statistical signifi-
cance was considered at P< 0.05.
Results
1,25(OH)2D3 ameliorated clinical symptoms of established
acute colitis model
As expected, the serum calcium concentrations in model
group (1.74 ± 0.07) mmol/L was lower than that in control
group (2.35 mmol/L ± 0.06 mmol/L, P< 0.01) and in
1,25(OH)2D3-treated group (2.60 mmol/L± 0.07 mmol/L,
P< 0.01). DSS caused the damage of the colon mucosal
barrier, leading to gut inflammation and weight loss. We
observed that mice in the model group had significantly
greater weight loss than that in the control group from
day 3 to day 8. Mice in 1,25(OH)2D3-treated group had
similar degree of weight loss as mice in the model group
from day 3 to day 8. However, mice in the 1,25(OH)2D3-
treated group had rapid weight recovery from day 9 to day
21 than those in the model group (Figure 1A) and the
AUC of BW in the model group was smaller than
that in the control group (1841.75 ± 52.11 vs 2195.60 ±
21.26, P< 0.01) and in the 1,25(OH)2D3-treated group
(1841.75± 52.11 vs 1902.64 ± 31.61, P< 0.01). Similarly,
mice in the 1,25(OH)2D3-treated group had firmer stool
and less blood in the stool than those in the model group
from day 9 to day 21. DAI, consisting of weight loss, stool
consistency and OB, were measured daily, and the per-
centage of weight change of model group was shown in
Figure 1B and the AUC of DAI in model group was lar-
ger than that in the control group (43.78± 8.95 vs
0.00± 0.00, P< 0.01) and in the 1,25(OH)2D3-treated
group (43.78± 8.95 vs 32.52± 6.49, P< 0.01).
1,25(OH)2D3 inhibited colonic inflammation
Mice in the model group had significantly worse macro-
scopic inflammation than those in the 1,25(OH)2D3-
treated group (Figure 1C and D). Colon shortening was
used as a marker of inflammation. Consistent with the
macroscopic inflammatory score, we found that by day
8, the colon length, in the model group was shorter
than that in the control group (4.88 ± 0.63 cm vs
6.80 ± 0.27 cm, P< 0.01) and in the 1,25(OH)2D3-treated
Figure 1 The inflammation in the DSS-induced model of acute colitis. (A) BW, shown as percentage of weight change, was assessed daily
and represented from day 0 to day 21. Compared to the control group, the model group displayed a more weight loss of BW. (B) DAI, comprised
of weight loss, stool consistency and OB, was shown. (C) Representative photographs of colon at the end of experiment were shown for control
group (a), model group (b), and 1,25(OH)2D3-treated group (c). (D) Macroscopic inflammation was assessed and shown. (E) The length of the
colon was quantitated and shown. (F) MPO enzymatic activity was measured and shown. (G) Representative H&E stained histology from control
group (a), model group (b) and 1,25(OH)2D3-treated group (c) (H&E staining; original magnifications, ×200). (H) Colon histological scores in
control, model and 1,25(OH)2D3-treated group were shown. (I and J) The total number of mononuclear cells from MLNs and LP was more in the
model group compared with that in the control group. Data were expressed as mean± SD. aP< 0.01 vs model group; bP< 0.01 vs control group.
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(Figure 1E). In addition, mice in the model group had
significantly higher MPO activity than those in the
1,25(OH)2D3-treated group (0.92 ± 0.16 vs 0.61 ± 0.11,
P< 0.01) and the control group (0.92 ± 0.16 vs 0.48± 0.10,
P< 0.01) (Figure 1F).
Compared to the control group, histological examin-
ation of the colon in the model group showed extensive
ulceration of the epithelial layer, edema, crypt damage of
bowel wall, fibrosis of the muscularis mucosae, infiltration
of granulocytes and mononuclear cells into the mucosa.
Compared to mice in the model group, the mice treated
with 1,25(OH)2D3 had a reduced DSS-induced histologic
colitis (Figure 1G). Histologic score includes: severity of
inflammation, extent of injury, crypt damage, each score
was multiplied by a factor equivalent with the percentage
of tissue involvement, then the histology score is the sum
of all parts of score. Our data showed that histology score
in the model group had significantly higher than that in
the control group (8.60 ± 2.20 vs 5.00± 0.00, P< 0.01),
however, histology score in the 1,25(OH)2D3-treated
group had no significantly lower than that in the model
group (7.40± 0.80 vs 8.60± 2.20, P> 0.05) (Figure 1H).
The number of mononuclear cells from the MLNs and LP
was more in the model group than that in the control
group (MLNs: 80.33 × 106 ± 14.51 × 106 vs 30.67×
106 ± 3.06× 106, P< 0.01; LPMC: 1.5 × 106 ± 0.5 × 106 vs
0.3 × 106 ± 0.1 × 106, P< 0.01). Compared to mice of the
model group, mice treatment with 1,25(OH)2D3reduced
the number of mononuclear cells from the MLNs and LP
(MLNs: 42.67 × 106 ± 2.52× 106; LP: 0.4 × 106 ± 0.1 × 106,
P< 0.01) (Figure 1I and J). To determine the anti-
inflammatory effect of 1,25(OH)2D3 on the DSS-
induced colitis, inflammatory markers were used for
immunohistochemistry including TNF-α and IFN-γ on
colon tissues in the control group(Figure 2A a and
Figure 2B a), the expressions of the TNF-α and IFN-γ
were not seen and there were significantly increased
expressions of the TNF-α and IFN-γ in the model
group(Figure 2A b and Figure 2B b) than those in the
1,25(OH)2D3-treated group(Figure 2A c and Figure 2A c).
The protein levels of these inflammatory cytokines in the
model group were higher than those in the control
group by Western blot (TNF-α: 0.69± 0.04 vs 0.54± 0.03,
P< 0.01; IFN-γ: 0.64± 0.03 vs 0.33± 0.03, P< 0.01)
and in the 1,25(OH)2D3-treated group (TNF-α:
0.69± 0.04 vs 0.63± 0.04, P< 0.01; IFN-γ: 0.64 ± 0.03 vs
0.55± 0.02, P< 0.01) (Figure 2C and D). Mice treated
with 1,25(OH)2D3 had reduced mRNA levels of inflam-
matory cytokines when compared to those in the model
group (TNF-α: 4.48± 0.08 vs 8.34± 0.11, P< 0.01; IFN-γ:
8.5 ± 0.34 vs 14.18 ± 0.86, P< 0.01) (Figure 2E). Together,
these data indicated that 1,25(OH)2D3 may ameliorate
the inflammation in the colitis model.1,25(OH)2D3 attenuated the DSS-induced paracellular
permeability
To investigate the effect of 1,25(OH)2D3 on paracellular
permeability, we examined intestinal permeability in ani-
mals subject. One of measures of permeability was bac-
terial translocation. Our study showed 1,25(OH)2D3
significantly reduced bacteria translocation to the MLNs
in the 1,25(OH)2D3-treated group when compared to
the model group (Figure 3A and B). Another measure of
intestinal permeability was FITC-D permeability. Our
data showed that the mice in the 1,25(OH)2D3-treated
group had a lower intestinal permeability to 4-kDa
FITC-D when compared to that in the model group
(Figure 3C). Consistent with reduced bacterial trans-
location, there was a result that the blood LPS levels
in the 1,25(OH)2D3-treated group was lower than that
in the model group (Figure 3D). These results sug-
gested that 1,25(OH)2D3 may maintain intestinal epi-
thelial integrity by decreasing paracellular permeability.
1,25(OH)2D3 ameliorated DSS induced ultrastructural
changes
SEM was used to observe ultrastructural features of the
colon in different groups. We found that the colon in
the model group had severer loss of the mucosa with
typical histological inflammation, including crypt distor-
tion compared to that in the control group (Figure 3E
a, b). Additionally, a greater number of enterocytes
from the mice in the model group (Figure 3E c, d)
showed less of the glycocalyx, and more irregular of
the surface than that in the control group. Meanwhile,
mice treatment with 1,25(OH)2D3 showed ameliorated
ultrastructural changes (Figure 3E e, f ). These data sug-
gest that 1,25(OH)2D3 may reduce intestinal permeabil-
ity in part by preserving ultrastructural integrity of the
epithelial mucosa.
1,25(OH)2D3 prevented DSS-induced disruption of TJ
TJ complexes interact with the actin cytoskeleton at the ap-
ical end of the lateral membranes. To determine the
protective effect of 1,25(OH)2D3 on the DSS-induced dis-
ruption of TJ, TJ markers were used for immunohisto-
chemistry including zo-1, occludin and claudin-1 on colon
epithelium. In the control group, TJ proteins were seen on
the cellular membrane of the epithelial cells, mostly in the
spinous and granular layers. In the 1,25(OH)2D3-treated
group, the expression of the TJ increased in both the cellu-
lar membrane and cytoplasm of spinous and granular layers
in the mucosa. However, in the model group, expressions
of the TJ decreased in individual cells of the spinous and
granular layers (Figure 4A and B). To determine whether
1,25(OH)2D3 could prevent DSS-induced reduction in TJ
expression, we performed real time Q-PCR analysis for TJ
markers message levels (Figure 4C). We demonstrated that
Figure 2 Effect of 1,25(OH)2D3 on the expressions of TNF-α and IFN-γ. (A and B) Expressions of TNF-α and IFN-γ proteins were analyzed by
immunohistochemistry in colon tissue from control group (a), model group (b) and 1,25(OH)2D3-treated group (c) (Immunohistochemistry
staining; original magnifications, ×200). (C and D) Expressions of TNF-α and IFN-γ proteins in colon tissue were analyzed by Western blot.
(E) Expressions of TNF-α mRNA and IFN-γ mRNA in colon tissue were analyzed by Real time Q-PCR. Data were expressed as mean± SD.
aP< 0.01 vs model group; bP< 0.01 vs control group.
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http://www.biomedcentral.com/1471-230X/12/57when compared to TJ expressions in control group, in the
model group there were a significantly reduced expressions
in zo-1, occludin and clandin-1 (0.46±0.03 vs 1±0.07,
0.36±0.02 vs 1.00±0.04, 0.85±0.05 vs 1.00± 0.05, respect-
ively; P< 0.01). We also found that TJ marker expressions
in the 1,25(OH)2D3-treated group were also significantly
higher than that in the model group (zo-1: 0.97±0.04,
occludin: 0.98±0.01, clandin-1: 1.00±0.04; P< 0.01)
(Figure 4D and E), which suggested the importance of1,25(OH)2D3 to maintain the integrity of the junction
complex.
The effect of 1,25(OH)2D3 on the structure and function
of the junction complexes in vitro
To further address molecular mechanisms of the pro-
tective role of 1,25(OH)2D3 in intestinal barrier function,
we used an established in vitro Caco-2 cells culture sys-
tem. Caco-2 cells formed TJ when grown to monolayer
Figure 3 1,25(OH)2D3 attenuated the loss of intestinal barrier during DSS-induced colitis model. (A) Detection of viable bacteria in MLNs
were shown for control group (a), model group (b) and 1,25(OH)2D3-treated group (c). (B) Differences in incidence of bacterial translocation were
quantitated and shown, (C) Quantification of serum FITC-D, a measure of intestinal barrier function, was shown. (D) The levels of endotoxin were
compared between control group, model group and 1,25(OH)2D3-treated group. Data were expressed as mean± SD.
aP< 0.01 vs model group;
bP< 0.01 vs control group. (E) The ultrastructural features were observed by SEM. The colon mucosa in the control group was regular without
histological lesion, (a, ×500; b, ×2 000); In the model group, the mucosa was severe loss, with histological lesions including crypt distortion and
abscesses, (c, ×500; d, ×2 000); Areas with histological lesions in the 1,25(OH)2D3-treated group were significantly ameliorated; However,
compared with the control group, there were less lesions and the crypt distortion and abscesses were less severer. Futhermore, crypt openings
were disposed in rows. (e, ×500; f, ×2 000).
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Figure 4 Effect of 1,25(OH)2D3 on colonic epithelial junctions. (A) Expressions of zo-1, occludin and claudin-1 were examined by
immunostaining for control, model, and 1,25(OH)2D3-treated group. Magnification: ×200. (B) Immunoflorescent stain with anti-claudin-1 (red),
anti-oocludin (red) and anti-zo-1 (green) antibody was shown. Notes of the zo-1, occludin and claudin-1 staining were markedly decreased in the
model group compared with that of the control and 1,25(OH)2D3-treated group. (C) Expressions of zo-1, occludin and clandin-1 genes were
performed and shown by real time Q-PCR analysis. (D and E) Expressions of TJ proteins in the colon were assessed by Western blot. In model
group, expressions of zo-1, occludin and claudin-1 were decreased markedly compared with that of control group. Data were expressed as
mean± SD. aP< 0.01 vs model group; bP< 0.01 vs control group.
Zhao et al. BMC Gastroenterology 2012, 12:57 Page 10 of 14
http://www.biomedcentral.com/1471-230X/12/57
Zhao et al. BMC Gastroenterology 2012, 12:57 Page 11 of 14
http://www.biomedcentral.com/1471-230X/12/57on membrane filters. As in the case of Caco-2 cells, the
addition of 1,25(OH)2D3 to the Caco-2 cells for 48 h
increased levels of TJ proteins and mRNA such as zo-1,
claudin-1, and occludin, and the optimum dose occurred
at 10-8 M (Figure 5A, B and C). Further examination of
these Caco-2 cell monolayer with TEM revealed intact
TJ, desmosomes, microvillus and brush border on the
apical side of Caco-2 cell monolayer in the 1,25(OH)2D3-
treated group (Figure 5D). Consistently, immunostaining
with anti-zo-1, claudin-1, and occludin antibodies
showed that 1,25(OH)2D3 (10
-8 M) markedly enhanced
TJ expression in the Caco-2 monolayer, and reflected by
bright staining in the membranes of the treated cells.
When the cells were incubated with 2% DSS for 2 h, the
TJ on the monolayer was markedly disrupted. In con-
trast, in the presence of 1,25(OH)2D3, the TJ was resist-
ant to the DSS damage and remained intact, as
evidenced by a strong staining of the zo-1, claudin-1,
and occludin on the membranes between the cells
(Figure 5E). When Caco-2 monolayer was incubated with
2% DSS, the TEER gradually decreased over 6 h in the
DSS group. However, in the 1,25(OH)2D3-treated cells,
the TEER was moderately reduced over the following
6 h (Figure 5F). Interestingly, FITC-D permeability
results showed that DSS increased the FITC-D perme-
ability in the DSS group, compared with that of the vehi-
cal group (51.83 ± 2.48 vs 5.5 ± 1.05, P< 0.01), while the
administration of 1,25(OH)2D3 (10
-9 M, 10-8 M, 10-7 M)
afforded cytoprotection against DSS-induced monolayer
hyper-permeability of Caco-2 cell monolayer (18.5 ± 1.05
vs 51.83 ± 2.48, 8.17 ± 1.17 vs 51.83 ± 2.48, 18.5 ± 1.05 vs
51.83 ± 2.48, P< 0.01) in the 1,25(OH)2D3-treated cells.
Our data showed that 1,25(OH)2D3(10
-8 M) had a lower
monolayer permeability to FITC-D when compared to
that 1,25(OH)2D3(10
-9 M, 10-7 M). Therefore, the opti-
mal concentration of 1,25(OH)2D3 on Caco-2 is 10
-8 M
for FITC-D permeability (Figure 5G). These data suggest
that 1,25(OH)2D3 might help to maintain epithelial bar-
rier integrity by preserving the expression of junction
proteins and increase its resistance to DSS damage.
These in vitro results are consistent with the observation
in vivo that 1,25(OH)2D3 reduces DSS induced colitis in
part by preserving TJ integrity of the epithelial mucosa.
Discussion
The intestinal mucosal integrity is a physical and meta-
bolic barrier against toxins and pathogens in the lumen.
The barrier regulates macromolecule trafficking between
the lumen and the internal milieu and protects the host
by preventing harmful solutes, microorganisms, toxins,
and luminal antigens from entering the body [36]. Com-
promise in intestinal barrier function can result in an
increased exposure of the host to luminal antigens and
pathogens, leading to inflammation [37]. The epithelialbarrier function is largely determined by intercellular TJ.
The TJ are responsible for restricting paracellular move-
ment of compounds across the intestinal mucosa
[38,39].
1,25(OH)2D3 was found to protect the intestinal mu-
cosa from various insults [40]. For example, 1,25(OH)2D3
may enhance defense mechanisms in the gastrointestinal
mucosa and prevent mucosal injury in IBD [16]. In the
present study, administration of 1,25(OH)2D3 was shown
to ameliorate signs and symptoms of inflammation, such
as colon shortening, weight loss, and increased DAI. In-
testinal mucosa has crucial functions in regulating intes-
tinal homeostasis by strictly protecting the subepithelial
compartment from potentially noxious luminal com-
pounds [41,42]. Kong et al. [6] have proved that vitamin
D deficiency may compromise the mucosal barrier, lead-
ing to increased susceptibility to mucosal damage and
increased risk of IBD. Intestinal barrier dysfunction is one
of the major contributing factors in multiple pathological
conditions of the gastrointestinal tract. An increased per-
meability in the TJ may provide a major site for both
infection and establishment of inflammation in the gut
[43-45]. Bacterial translocation is believed to occur via a
paracellular pathway through the epithelial cells. Our
data showed 1,25(OH)2D3 might have a protective effect
on barrier integrity by maintaining the expression of TJ
proteins, thereby reducing the severity of gut inflamma-
tion. This study adds to previous reports suggest that
bioavailability of 1,25(OH)2D3 is an important contribut-
ing factor for determining the epithelial integrity.
Once the mucosal barrier is breached, the submucosa
is exposed to a vast pool of luminal antigens, including
food and bacteria, thereby engaging the innate immune
responses including increased production in pro-
inflammatory cytokines TNF-α and IFN-γ. We showed
that the addition of 1,25(OH)2D3 was shown to amelior-
ate the DSS-induced high-expression in TNF-α and
IFN-γ. The reduction in pro-inflammatory cytokines by
1,25(OH)2D3 may be either due to its direct suppressive
effect on the expression of these pro-inflammatory cyto-
kines or due to the effect on maintenance of epithelial
barrier function, leading to a reduction in foreign lu-
minal antigenic load, and a full activation of the innate
immune system.
Conclusion
In summary, our data suggest that 1,25(OH)2D3 may
be effective in ameliorating DSS-induced acute colitis,
gauged by reducing clinical symptom, decreasing
macroscopic and histological inflammation, enhancing
epithelial cell resistance to injury and suppressing pro-
inflammation responses to luminal antigens. Although
some parts of the histology score are not obviously
ameliorated by 1,25(OH)2D3, we think that there are
Figure 5 Effect of 1,25(OH)2D3 on the barrier function in vitro. (A and B) Induction of TJ proteins by 1,25(OH)2D3 in Caco-2 cells. Caco-2 cells
were treated with indicated dose of 1,25(OH)2D3 for 48 h, and cell lysates were analyzed by Western blot. Western blot analysis showed induction
of zo-1, occludin and claudin-1 proteins after 48 h of adding to1,25(OH)2D3. (C) Expressions of zo-1, occludin, claudin-1 mRNA were assessed after
adding to 1,25(OH)2D3 by real time Q-PCR. (D) TEM showed the disruption of the TJ, desmosomes, microvillus and brush border on the apical
side of Caco-2 cell monolayer in the model group compared to that of the vehicle and 1,25(OH)2D3-treated group. (E) Cell monolayer was
stained for occludin (red), claudin-1 (red) and zo-1(green) by immunofluorescence staining, noting the disruption of the TJ and reduction of
fluorescence intensity in DSS group. (F) Effect of 1,25(OH)2D3 on TEER. A dose-dependent recovery of TEER with 1,25(OH)2D3-treated was seen.
(G) Paracellular FITC-D was measured with or without 2% DSS in the absence or presence of 1,25(OH)2D3 at 10
−9, 10−8, 10−7 M (administered
2 h prior to DSS) for 48 h, 1,25(OH)2D3 attenuated the epithelial hyperpermeability induced by DSS. Data were expressed as mean± SD.
aP< 0.05 vs vehicle group, bP< 0.05 vs DSS group.
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http://www.biomedcentral.com/1471-230X/12/57some reasons, such as: a short treatment time, a very
slow process of pathological change and so on. How-
ever, the effect of 1,25(OH)2D3 in IBD is worth further
study. Our data showed that 1,25(OH)2D3 may play an
important role in maintaining epithelial integrity and
regulating the innate immune responses. The thera-
peutic potential of 1,25(OH)2D3 for the treatment of
human colitis warrants exploration.
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